We are focused on the clinical development of novel therapies for cancer. Our programs include a potential best-in-class HDAC inhibitor, Pracinostat, isoflavone-based compounds ME-344 and ME-143, and a PI3K delta inhibitor PWT143.
[ Read more ]
MEI Pharma Announces Pricing of Public Offering of Common Stock
[ October 25, 2013 ]
Click here for our 2013 Annual Review